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Abstract
Background: Patients with somatostatin receptor-expressing neuroendocrine tumours
can be treated with intravenously administered 177Lu-octreotate. Few patients are cured
with the present protocol due to the current dose limitation of normal organs at risk, such
as the kidneys. By locally administering 177Lu-octreotate to the liver for the purpose
of treating liver metastases, a substantially reduced absorbed dose to organs at risk
could be achieved. The development of such a technique requires the capability of
measuring the 177Lu activity concentration in tissues in vivo. The aim of this study was to
evaluate different performance parameters of two commercially available intraoperative
gamma detectors in order to investigate whether intraoperative gamma detector
measurements could be used to determine 177Lu activity concentration in vivo.
Results: Measurements were made using different sources containing 177Lu. Response
linearity, sensitivity, spatial resolution and its depth dependence, organ thickness
dependence of the measured count rate and tumour detectability were assessed for two
intraoperative gamma detectors. The two detectors (a scintillation and a semiconductor
detector) showed differences in technical performance. For example, the sensitivity was
higher for the scintillation detector, while the spatial resolution was better for the
semiconductor detector. Regarding organ thickness dependence and tumour detectability,
similar results were obtained for both detectors, and even relatively small simulated
tumours of low tumour-to-background activity concentration ratios could be detected.
Conclusions: Acceptable results were obtained for both detectors, although the
semiconductor detector proved more advantageous for our purpose. The measurements
demonstrated factors that must be corrected for, such as organ thickness or dead-time
effects. Altogether, intraoperative gamma detector measurements could be used
to determine 177Lu activity concentration in vivo.
Keywords: Intraoperative gamma detectors, Performance evaluation, 177Lu,
Neuroendocrine tumours
Background
Neuroendocrine tumours (NETs) originate in neuroendocrine glands and are often
characterised by overexpression of hormone receptors and their ability to store and
secrete peptides and neuroamines [1]. They are generally small and slow growing and
their symptoms are often vague or even indiscernible [2]. Thus, NETs have often
metastasised by the time of diagnosis and the possibility of cure by surgical removal of
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the primary tumour is unlikely. There are several different systemic treatment options
for these patients, including the use of somatostatin analogues, chemotherapy, and tar-
geted therapies including radionuclide therapy [3]. Specifically, treatment with the som-
atostatin analogue 177Lu-octreotate has shown promising results [4–11]. However, few
patients achieve complete remission and there is a need for improvement of
177Lu-octreotate treatment, with some options being (1) increasing the therapeutic
effect on tumour tissue or (2) reducing the uptake in healthy organs at risk [12].
By lowering the uptake in organs at risk, the administered activity, and hence the
absorbed dose to the tumour, could be increased.
For systemic 177Lu-octreotate treatment, kidneys and bone marrow are the main or-
gans at risk and therefore restrict the activity that can be administered to the patient
without causing severe negative side effects due to high absorbed doses [5, 6, 8, 13–15].
By introducing a new treatment method, based on local administration of 177Lu-
octreotate to the liver, where NET metastases often are localised, a substantially
lower uptake in kidneys and bone marrow could be achieved. Using this treatment
method, the liver would be the main organ at risk and the development and opti-
misation process would require detailed and accurate determination of 177Lu-
octreotate concentration in the liver, but also in other tissues such as tumours and
the kidneys, in vivo. Knowledge of time-dependent activity concentrations of 177Lu-
octreotate is required for calculation of absorbed doses.
An intraoperative gamma detector is a small handheld instrument for gamma radiation
measurements [16]. Since 177Lu emits both electrons and photons, it is possible that such
a detector could be used to accurately quantify 177Lu concentration during a therapy situ-
ation. Normally, intraoperative gamma detectors are used for radioguided surgery, where
the purpose is to locate and surgically remove small lesions after injection of a diagnostic
radiopharmaceutical [17]. This method may offer clinical benefit for patients by minimis-
ing the invasiveness of the surgery or enabling more tumour tissue to be removed. Radio-
guided surgery is used for many different clinical conditions, one of which is NET using
111In-octreotide as the tracer. Several studies have demonstrated that intraoperative detec-
tors can detect even relatively small tumours if properly used [18–22].
During the last few decades, many studies have evaluated the technical performance
of intraoperative gamma detectors [23–35]. Most of these were performed for diagnos-
tic radionuclides (e.g., 99mTc or 111In). More recently, the possibility of using intraoper-
ative detectors to locate small lesions in patients injected with therapeutic
radionuclides, such as 177Lu and 90Y, has been investigated [36–38]. However, the tech-
nical performance of intraoperative gamma detectors when used for therapeutic radio-
nuclides remains to be studied in more detail.
The aim of this study was to measure different performance parameters of two com-
mercially available intraoperative gamma detectors in order to investigate the possibility
of using intraoperative gamma detection for determining 177Lu activity concentration
in small tissue regions in vivo.
Methods
The performance of two intraoperative gamma detectors was assessed using different
phantoms containing 177Lu (IDB Holland BV, Baarle-Nassau, the Netherlands). The pa-
rameters assessed in this study included response linearity, sensitivity, spatial resolution
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and its depth dependence, organ thickness dependence and tumour detectability. 177Lu
activity was determined using a well-type ionisation chamber (CRC-15R, Capintec,
Ramsey, NJ, USA).
Gamma detectors
The two intraoperative gamma detectors evaluated were the Gamma Finder II (World
of Medicine GmbH, Berlin, Germany) and the Navigator GPS with the probe model
“Standard lymphatic mapping” (Dilon Diagnostics, Newport News, VA, USA) (Fig. 1).
The Gamma Finder II, hereafter called detector A, contains a scintillation detector with
a CsI(Tl) crystal of 4.5 mm in diameter and with a height of 9 mm. The tungsten colli-
mator has an aperture of 5 mm in diameter and a wall thickness of 3 mm. Detector A
is wirelessly operated and the measured count rate is shown in counts per second (cps)
in a display on the detector. The Navigator GPS, hereafter called detector B, contains a
semiconductor detector. It has a 2-mm-thick octagonal CdTe crystal (with a dimension
of 8 mm between two opposite corners) and a tungsten collimator with an aperture of
7.11 mm in diameter and a wall thickness of 2.97 mm. Detector B consists of a probe
connected by a cable to a control unit, where the measured count rate is displayed in
cps. Both detectors offer the capability of performing a 10-s measurement, during
which the total number of counts is recorded. The reason why our study was limited to
these two detectors was that those were only ones to which we had access.
The measureable photon energies from 177Lu are 113 and 208 keV, with an emission
yield of 6.17 and 10.3%, respectively [39]. Detector A has a non-adjustable low-energy
Fig. 1 Schematic view of the geometrical crystal and collimator design of the two detectors. For detector
A, information from the manufacturer about the distance from the crystal to the distal end of the collimator
was not available, indicated by the question mark and the arrow inside the CsI(Tl) crystal. Note that only the
tips of the two detectors are shown
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threshold of 110 keV, that is, all registered photons with energy above 110 keV will be
counted. Detector B has a set of selectable non-adjustable energy windows designed for
different diagnostic radionuclides (99mTc, 111In, 125I and 131I). A 20% energy window
centered over the 99mTc energy peak at 141 keV (range 112–169 keV) was used for all
detector B measurements.
Linearity and sensitivity
The response linearity of the two detectors was investigated using point sources.
Twenty-six point sources (0.19–29 MBq) were prepared by placing small drops of
177Lu at the bottom of 1.5-ml Eppendorf tubes. The detector was placed immediately
in front of each point source. The measurement time was adjusted so that at least 1000
counts were collected. The sensitivity of the two detectors, given as count rate per unit
activity of the point source, was calculated from the data obtained in the measurements
of response linearity.
Spatial resolution and its depth dependence
To determine the spatial resolution and its depth dependence, a line source was created
by filling a narrow plastic tube (inner diameter 0.86 mm) with 177Lu. The activity con-
centration in the tube was 500 MBq/ml, corresponding to 0.29 MBq/cm tube length.
This line source was placed at different depths, ranging from 0 to 80 mm, in a block
phantom of tissue-equivalent plastic (polymethyl methacrylate). The detector was
mounted in a holder and positioned immediately above the phantom surface. The de-
tector was then moved stepwise laterally across and perpendicularly away from the line
source from −70 to +70 mm, where the position 0 mm corresponds to the position
where the detector was centered over the line source. For each position, the number of
counts during 10 s was recorded, resulting in about 100–10,000 counts depending on
the distance from the line source. The spatial resolution was determined as the full-
width-at-half-maximum (FWHM) and as the full-width-at-tenth-maximum (FWTM) of
the line profiles obtained.
Organ thickness dependence
To assess the dependence of organ thickness, a gel phantom was created from 2% agar-
ose gel blocks, containing a homogeneous distribution of 177Lu with an activity concen-
tration of 23 kBq/ml. To create the gel blocks, a mixture of tap water and 2% agarose
gel powder (Agarose A9539, Sigma-Aldrich Corporation, St. Louis, MO, USA) was
heated in a microwave oven until the gel powder was completely dissolved. Thereafter,
177Lu was added to the solution under agitation to obtain a homogeneous activity dis-
tribution. Lastly, the radioactive gel mixture was poured into moulds for solidification.
The dimension of each block was approximately 250 × 170 × 10 mm. These blocks were
stacked on each other to obtain thicknesses between 10 and 150 mm. The detector was
placed in a holder and positioned immediately above the surface and at the center of
the block. The measurement time for each thickness was adjusted so that at least 1000
counts were collected. Before each measurement, the height of the stack of blocks was
determined using a ruler, due to small differences in the exact dimensions among gel
blocks.
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Tumour detectability
To investigate the tumour detectability of the two detectors, a tumour phantom was
created by placing a 2% agarose gel sphere at the surface of a stack of 10 gel blocks (de-
scribed earlier). The gel sphere was created by pouring radioactive gel mixture into a
spherical mould. The gel sphere, simulating a small tumour, contained a higher activity
concentration than the gel blocks, simulating the background, that is, the surrounding
normal tissue. Measurements were made for different sphere sizes (diameter of 5, 10,
15 and 20 mm) and ratios between the activity concentration in the tumour sphere and
that in the background (T/Bgr, 2, 5, 15 and 30). These sizes and ratios were chosen to
be relevant for clinical situations [40–42]. The detector was mounted in a holder and
positioned immediately above the surface of the stack of gel blocks. Measurements
were made in two positions, (1) over the tumour sphere, where a number of counts,
CT, was obtained and (2) over the background, where a number of counts, CBgr, was ob-
tained (Fig. 2). The measurement time for each position was adjusted so that at least
1000 counts were collected for each position. The tumour detectability measurements
were carried out one day after the measurements of organ thickness dependence.
Therefore, the activity concentration in the background gel blocks was 20 kBq/ml in-
stead of 23 kBq/ml, due to radioactive decay.
The homogeneity of the activity concentrations in the tumour phantom was evalu-
ated by measuring 16 random samples from the gel blocks and 10 random samples
from the gel tumour spheres in a gamma counter (Wallac 1480 Wizard 3”, Wallac Oy,
Turku, Finland).
Statistical analyses
For the measurements of organ thickness dependence, statistical analyses were per-
formed to determine the largest thickness where a statistically significant difference
could be seen when the signal intensity at that thickness, C, was compared to the signal
Fig. 2 The positions in which CT and CBgr was measured during the tumour detectability measurements.
The red gel tumour sphere placed at the surface on the left simulated a tumour, and the blue background
phantom simulated surrounding normal tissue
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intensity measured at the largest thickness, CMax (148 mm). Given a measurement time
of 20 s, the standard deviation (SD) of the difference between CMax and C, σ(CMax −C),
was calculated:





Differences between CMax and C were considered statistically significant (p < 0.05)
when they exceeded two SDs of the difference, that is 2 × σ(CMax − C).
For the tumour detectability measurements, statistical analyses were performed to de-
termine for which T/Bgr and tumour sphere sizes the difference between CT and CBgr
was statistically significant, given the measurement time of 20 s. The SD of the differ-
ence between CT and CBgr, σ(CT −CBgr), was calculated:
σ CT−CBgr
  ¼ ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃCT þ CBgr
p ð2Þ
Differences between CT and CBgr were considered statistically significant (p < 0.05)
when they exceeded two SDs of the difference, that is 2 × σ(CT −CBgr).
Results
Linearity and sensitivity
The response increased when the activity of the point source increased (Fig. 3). The
two detectors showed great differences in response. A linear response (±10%) was seen
for activities up to 1.3 and 12 MBq for detectors A and B, respectively. Both detectors
reached a maximum measurable activity. This maximum was about 5 times higher for
detector B (28 MBq) than that of detector A (6.1 MBq). The sensitivity was higher for
detector A than for detector B—1200 and 500 cps/MBq, respectively (Fig. 3).
Spatial resolution and its depth dependence
The line profiles acquired with the two detectors are shown in Fig. 4. The count rate
markedly decreased when the depth of the line source in the phantom increased. At
Fig. 3 Detector response given as count rate for point sources of different radioactivity. The lowest 4 and
13 activity levels were used to plot the trend line as linear response for detectors A and B, respectively
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lateral position 0 mm, the signal intensity decreased to 37 and 46% for 10-mm depth
compared with 0-mm depth for detectors A and B, respectively.
Detector B had better spatial resolution (lower FWHM and FWTM) than detector A
at all depths investigated (Table 1). The largest relative difference in FWHM (38%) was
seen at the 20-mm depth and the largest relative difference in FWTM (116%) was seen
at the 0-mm depth. Furthermore, the spatial resolution worsened with increasing line
source depth for both detectors.
Organ thickness dependence
When the thickness of the agarose gel phantom containing radioactivity increased, the
count rates of the detectors increased (Fig. 5). For thicknesses larger than about
100 mm, however, a saturation of the signal intensity could be seen. Specifically, the
largest thickness where a statistically significant difference was found when the signal
intensity was compared with the signal intensity measured at the largest thickness
(148 mm) was 110 mm for both detectors.
Tumour detectability
Generally, the ratio between the number of counts over the tumour sphere and that
over the background (CT/CBgr) increased both with increasing T/Bgr and size of the
tumour sphere (Fig. 6). Furthermore, detector B showed somewhat higher CT/CBgr than
detector A. However, the combinations of T/Bgr and tumour sphere size where a statis-
tically significant difference (p < 0.05) between CT and CBgr was found were the same
Fig. 4 Detector response of the two detectors for the 177Lu line source located at a depth of 0–80 mm.
The y-axes show relative count rate, i.e. signal intensity values normalised to the signal intensity measured
at lateral position 0 mm at a depth of 0 mm. The uncertainty in the position of the detector was about
±0.5 mm for each measurement
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for both detectors. Given the measurement time of 20 s, a statistically significant differ-
ence could be seen for all combinations except for the two smallest sizes (5 and
10 mm) for T/Bgr = 2 and for the smallest size (5 mm) for T/Bgr = 5.
The homogeneity (SEM/mean) for the different parts of the agarose gel tumour
phantom was 1.8% for the tumour spheres and 2.2% for the background blocks.
Discussion
The development of a new treatment method where 177Lu-octreotate is locally adminis-
tered to the liver requires quantification of 177Lu activity concentration in tumours and
normal tissues in vivo. For this therapeutic situation, both the choice of radionuclide
(with lower yield of countable photons emitted) and the activity concentration will be
much different from the diagnostic situation. Since intraoperative gamma detectors are
designed for measurements of diagnostic radionuclides and low amounts of activity,
the maximum measurable activity was a parameter of interest in this study. At high
Table 1 Spatial resolution, given as full-width-at-half-maximum (FWHM) and full-width-at-tenth-
maximum (FWTM), for the two detectors when the 177Lu line source was placed at different depths
in the phantom of tissue-equivalent plastic. For some depths, FWTM was larger than 140 mm and
could thus not be determined
FWHM (mm) FWTM (mm)
Depth (mm) Detector A Detector B Detector A Detector B
0 11 9.9 39 18
10 27 20 88 46
20 41 30 124 77
40 68 49 >140 135
60 93 73 >140 >140
80 113 91 >140 >140
Fig. 5 The organ thickness dependence of the two detectors. The count rate was determined for
homogeneously distributed 177Lu in agarose gel with a thickness of 10–148 mm. Both detectors showed
saturation at about 110 mm. The star indicates the largest thickness where a statistically significant
difference was found compared with the signal intensity at 148 mm
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activity levels, part of the signal will be lost due to dead-time effects in the detector.
This effect can be corrected for if the detector response curve is known. A more signifi-
cant problem will occur if the activity in a target region is too high to be measured at
all. This problem occurred for both detectors. However, detector B proved to be better
suited for measurements of high activities compared with detector A, permitting about
5 times higher activity to be quantified. One reason for this was the higher sensitivity
of detector A, leading to a higher count rate for a given activity. Another reason was
that detector B could reliably measure higher count rates than detector A. Unfortu-
nately, the measurement time of detector B could not be set to less than 10 s. Detector
B failed to report the total number of counts during 10 s when the count rate exceeded
9999 cps, due to a limitation in the number of figures of the display window. The max-
imum count rate of detector A was instead reached at around 6000 cps; higher count
rates resulted in an error message, probably due to problems with dead-time effects.
The difference in sensitivity also affected the range in which a linear response could be
seen, which was almost ten times higher for detector B than for detector A. However,
correction for dead-time effects can be done according to the shape of the response
curve and thereby yield the actual activity in the tissue of interest. With these results in
mind, a low sensitivity may be preferable for intraoperative gamma detector measure-
ments in therapeutic situations, where large amounts of activity or activity concentra-
tions are involved.
The difference in overall sensitivity between the two evaluated detectors was large,
1200 cps/MBq for detector A compared with 500 cps/MBq for detector B. With the
two measurable photon energies from 177Lu (113 and 208 keV) in mind, the difference
in energy window settings of the two detectors are likely to have substantially contrib-
uted to the difference in sensitivity. The energy window threshold of 110 keV of de-
tector A means that both 177Lu photon energies was measured. The energy window of
detector B (112–169 keV), on the other hand, rejected most 208-keV photons. Further-
more, differences in sensitivity could also be explained by collimator geometry. Unfor-
tunately, information on the collimator length of detector A was not available from the
Fig. 6 The ratio between the number of counts over the tumour sphere (CT) and that over the background
(CBgr) vs. the diameter of the tumour sphere, CT/CBgr, was generally higher for detector B than for detector
A. The stars indicate the combinations of T/Bgr and tumour sphere size where a statistically significant
difference (p < 0.05) between CT and CBgr could be detected
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manufacturer (Fig. 1). Therefore, comparison of FOV size between the two detectors at
different distances was not possible. Lastly, scintillation crystals are often thicker than
semiconductor crystals, which was the case for the two detectors evaluated here. De-
tector A has a crystal thickness of 9 mm (CsI(Tl), effective atomic number, Zeff = 54),
compared with the 2-mm-thick crystal of detector B (CdTe, Zeff = 52), and the detec-
tors had similar Zeff values. With a thicker crystal, a larger portion of the incident radi-
ation will interact, and the sensitivity will increase. This also contributes to the higher
sensitivity of the scintillation detector (detector A).
Detector B had better spatial resolution than detector A, more apparent for FWTM
than for FWHM (Fig. 4). FOV substantially affects spatial resolution, and it is likely that
detector B has the smaller FOV. Furthermore, collimator material and thickness are
important. Both detectors had very similar collimation, about 3-mm thick tungsten. A
thicker collimator would result in better rejection of radiation originating from regions
outside the FOV, and thus a better spatial resolution, but also a lower overall sensitivity.
Therefore, increasing the collimator wall thickness for determination of 177Lu activity
concentration in vivo during a therapy situation could be beneficial, both to reduce
contribution from adjacent tissues and also to reduce sensitivity. The energy window
setting may also influence the spatial resolution. The low-energy threshold of 110 keV
of detector A allowed for a larger part of scattered radiation to be detected, compared
with the narrower energy window of detector B (112–169 keV). Since scattered radi-
ation generally decreases spatial resolution, this could explain the superior results of
detector B.
Overall, the collimation of both detectors was acceptable, with a lateral response of
about 5–10% (the count rate at a lateral distance of 20 mm from the line source relative
to that at 0 mm from the line source). This can be compared with the results by Benjegård
et al., who reported a much higher lateral response, of about 10–40%, for similar types of
intraoperative detectors [31]. This large difference could be explained by differences in ra-
dionuclides and collimator material used. Benjegård et al. used 111In, with higher photon
energies (170 and 240 keV) and thus greater penetrability than those of 177Lu (113 and
208 keV). Furthermore, the detector with the highest lateral response (40%) in the study
by Benjegård et al. had a 3-mm-thick lead collimator, while the detectors evaluated in this
study had collimators made of tungsten, which has slightly better attenuation properties
than those of lead.
During the measurements of organ thickness dependence, the count rate reached sat-
uration at large thicknesses for both detectors. The contribution from the bottom gel
slice to the detector signal decreased, both due to increased attenuation by the gel
blocks but also due to the increased geometrical distance. Theoretically, the count rate
should increase when the thickness increases also at very large thicknesses, but in prac-
tice this increase was so small that it was negligible and the signal response curve
reached a plateau. Dead-time effects in the detectors could also have contributed to this
plateau. To be able to correctly translate a measured count rate from a thick organ into
an activity concentration, it is important that the shape of this response curve is
known. The results from the measurements of organ thickness dependence could be
used for translation of a measured count rate into an activity concentration of 177Lu in
vivo. However, possible contribution from inhomogeneous activity distribution in the
tissue and 177Lu in deeper-located tissues should be considered.
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The ability of an intraoperative gamma detector to detect a tumour in surrounding
normal tissue depends on the size of the tumour, but also on the ratio of the activity
concentrations in the two tissues. Therefore, the tumour detectability results were af-
fected by both spatial resolution and overall sensitivity. The CT/CBgr values were gener-
ally higher for detector B than for detector A, indicating better tumour detectability for
detector B, due to the better spatial resolution of detector B. However, statistical ana-
lysis resulted in similar performance for both detectors for the tumour sizes and activ-
ity concentration ratios evaluated, probably due to the higher sensitivity of detector A.
Results from clinical studies where intraoperative gamma detectors were used for
radioguided surgery suggest that the lowest CT/CBgr level needed to detect a tumour in
surrounding normal tissue is around 1.2–1.5 [18, 21, 22, 43], but higher levels of up to
2 have been suggested as the ratio value corresponding to the lowest limit of detectabil-
ity [44–47]; the reason for this difference is probably due to the sensitivity of the de-
tector, the number of photons sampled and the biological uncertainties in radionuclide
concentration in tissues. Both detectors evaluated in the present work could be used
clinically, but the clinical application would decide which parameter is more important,
and thus which detector would be best. For low levels of activity concentration, sensi-
tivity may be more important than spatial resolution, and then detector A would be the
choice. However, for small structures/regions, such as a small tumour, spatial resolution
can be more important than sensitivity, and then, detector B would be better.
To our knowledge, this study is the first evaluation of intraoperative detection using
the therapeutic radionuclide 177Lu, and the sensitivities measured here were 1200 and
500 cps/MBq. Previous studies have reported sensitivities of 8400 cps/MBq [35], 3800–
7300 cps/MBq [30] and 250–2300 cps/MBq [34] for 99mTc and of 2800–6100 cps/MBq
for 111In [31]. While the sensitivities of the two detectors evaluated in the present study
are generally lower than those previously reported, a direct comparison is not com-
pletely accurate, since the experimental setup and the choice of radionuclide differed
among the studies. Both the emission yield (90.6 and 94.1% for 111In, 89.0% for 99mTc
and 6.17 and 10.4% for 177Lu [39]) and the available energy window settings, as well as
the source-detector distance (SDD), will substantially affect the measured sensitivities.
In contrast to sensitivity, spatial resolution is less dependent on the radionuclide. Re-
sults from other studies where similar experimental setups were used are summarised
in Table 2. Two of these studies included detector B in their evaluations, and these
values are presented separately. Overall, the values summarised in Table 2 are in about
the same range as those reported in other studies.
The main focus of this study was to investigate the possibility of determining 177Lu
activity concentrations in vivo. However, for evaluation of the effect of ionising radi-
ation on tumour and normal tissues, absorbed dose (rather than activity concentration)
is the physical quantity of interest. In order to translate activity concentrations to
absorbed doses, information about radionuclide biokinetics, absorbed fractions and
organ masses are needed [48]. Radionuclide biokinetics could be estimated by repeated
measurements of the activity concentration after 177Lu-octreotate administration, for
example, by an intraoperative detector or a gamma camera.
In summary, sensitivity and spatial resolution are closely related. A good spatial reso-
lution (low FWHM) comes at the expense of a loss in sensitivity, and vice versa. Nor-
mally, when the aim is to locate lesions after injection of a low amount of a diagnostic
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radionuclide, a low sensitivity is undesirable. In the case of a 177Lu-octreotate treat-
ment, where there same requirements to minimise the injected amount does not exists,
the level of activity is much higher and a high sensitivity is thus less crucial. An intra-
operative gamma detector with a good spatial resolution, and a lower sensitivity, is
therefore preferable for determination of 177Lu activity concentration in vivo.
Conclusions
The evaluated detectors showed differences in technical performance, especially con-
cerning sensitivity and maximum measureable activity. Still, when the detectors are
used for intraoperative measurement of 177Lu during therapy we believe that acceptable
results will be obtained for both detectors, probably with better results for detector B.
The study demonstrates the need to calibrate and evaluate detectors using phantoms
simulating the clinical situation and to correct for factors such as depth, organ thick-
ness and dead-time effects to be able to accurately determine 177Lu activity concentra-
tion in tissues in vivo. Altogether, the results indicate that intraoperative measurements
of 177Lu distribution in patients may be performed with satisfactory accuracy if accurate
corrections for the foregoing factors can be implemented.
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